Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Castration-resistant Prostate Neoplasms: full-pipeline trial registry
2 of 2 indexed Metastatic Castration-resistant Prostate Neoplasms trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Metastatic Castration-resistant Prostate Neoplasms: 2 US clinical trials tracked, 2 recruiting.
Metastatic Castration-resistant Prostate Neoplasms is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-castration-resistant-prostate-neoplasms
OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Metastatic Castration-resistant Prostate Neoplasms lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Castration-resistant Prostate Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Castration-resistant Prostate Neoplasms is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development
NCT07164443
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development
NCT05818683
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Castration-resistant Prostate Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Castration-resistant Prostate Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Castration-resistant Prostate Neoplasms page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Metastatic Castration-resistant Prostate Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Metastatic Castration-resistant Prostate Neoplasms trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Castration-resistant Prostate Neoplasms condition card totals 2 registered trials; most-linked intervention Cabazitaxel; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.